We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+5.25%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$358M
AUM Growth
+$34.6M
Cap. Flow
+$36.2M
Cap. Flow %
10.1%
Top 10 Hldgs %
49.91%
Holding
70
New
7
Increased
17
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$18.4M
2
HRMY icon
Harmony Biosciences
HRMY
+$13.9M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$9.9M
4
VERA icon
Vera Therapeutics
VERA
+$5.57M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$5.45M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$35.8M
2
TVTX icon
Travere Therapeutics
TVTX
+$5.06M
3
ILMN icon
Illumina
ILMN
+$4.21M
4
QURE icon
uniQure
QURE
+$3.21M
5
DYN icon
Dyne Therapeutics
DYN
+$2.69M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRYS icon
26
Krystal Biotech
KRYS
$10.6B
$4.88M 1.36%
61,000
+16,000
+36% +$1.26M
GILD icon
27
Gilead Sciences
GILD
$185B
$4.78M 1.33%
57,584
– –
AZN icon
28
AstraZeneca
AZN
$255B
$4.51M 1.26%
32,500
– –
PTCT icon
29
PTC Therapeutics
PTCT
$5.99B
$4.5M 1.26%
93,000
-51,000
-35% -$2.33M
ERAS icon
30
Erasca
ERAS
$6.82B
$4.28M 1.19%
+1,426,000
New +$5.19M
ACAD icon
31
Acadia Pharmaceuticals
ACAD
$5.12B
$4.06M 1.13%
216,000
+116,000
+116% +$2.21M
GMAB icon
32
Genmab
GMAB
$21B
$3.32M 0.93%
+88,000
New +$3.38M
TVTX icon
33
Travere Therapeutics
TVTX
$6.36B
$3.17M 0.88%
141,019
-238,000
-63% -$5.06M
ASND icon
34
Ascendis Pharma A/S
ASND
$16.4B
$3.15M 0.88%
29,400
– –
ZLAB icon
35
Zai Lab
ZLAB
$3.01B
$2.63M 0.73%
78,958
– –
JAZZ icon
36
Jazz Pharmaceuticals
JAZZ
$16.3B
$2.51M 0.7%
17,200
– –
CRBU icon
37
Caribou Biosciences
CRBU
$178M
$2.43M 0.68%
457,892
+200,000
+78% +$1.25M
APLS
38
DELISTED
Apellis Pharmaceuticals
APLS
$2.09M 0.58%
31,700
– –
KRTX
39
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$2M 0.56%
+11,000
New +$2.1M
DNLI icon
40
Denali Therapeutics
DNLI
$3.94B
$1.99M 0.56%
86,575
+48,575
+128% +$1.34M
NVCR icon
41
NovoCure
NVCR
$2.09B
$1.92M 0.54%
32,000
– –
LEGN icon
42
Legend Biotech
LEGN
$3.99B
$1.83M 0.51%
38,000
– –
GH icon
43
Guardant Health
GH
$22.6B
$1.75M 0.49%
74,500
– –
HALO icon
44
Halozyme
HALO
$12.1B
$1.74M 0.48%
+45,500
New +$2.13M
MIRM icon
45
Mirum Pharmaceuticals
MIRM
$6.08B
$1.62M 0.45%
67,500
– –
CRSP icon
46
CRISPR Therapeutics
CRSP
$5.74B
$1.55M 0.43%
34,200
– –
IONS icon
47
Ionis Pharmaceuticals
IONS
$10.4B
$1.54M 0.43%
+43,000
New +$1.61M
RCKT icon
48
Rocket Pharmaceuticals
RCKT
$397M
$1.08M 0.3%
63,000
– –
NBP
49
NovaBridge Biosciences American Depositary Shares
NBP
$219M
$1.07M 0.3%
310,499
– –
NVAX icon
50
Novavax
NVAX
$1.49B
$925K 0.26%
132,500
– –
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2023 Portfolio in Review

As of Q1 2023, International Biotechnology Trust held 70 positions worth $358M, up 11% from $324M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

International Biotechnology Trust deployed $36.2M of net new capital in Q1 2023, opening 7 new positions and adding to 17 existing holdings. Its largest new stake was Vertex Pharmaceuticals: 33,000 shares worth $10.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $5.06M trimmed.

  • International Biotechnology Trust's largest Q1 2023 buy was Vertex Pharmaceuticals: 33,000 shares worth $10.4M.
  • International Biotechnology Trust added most to Amgen in Q1 2023, an estimated $18.4M increase.
  • International Biotechnology Trust's biggest Q1 2023 reduction was Travere Therapeutics, cutting an estimated $5.06M.
  • International Biotechnology Trust fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $35.8M.
  • International Biotechnology Trust's ten largest holdings make up 50% of its $358M portfolio in Q1 2023.
  • International Biotechnology Trust opened 7 new positions and closed 6 in Q1 2023.
  • International Biotechnology Trust's portfolio value rose 11% quarter-over-quarter to $358M.

Based on International Biotechnology Trust's 13F filing for Q1 2023, filed 18 May 2023.